Inclusion Criteria:

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Histologically or cytologically confirmed Stage IIIB-IVB NSCLC

          -  For participants who have received prior neo-adjuvant/adjuvant chemotherapy or
             chemoradiotherapy with curative intent for non-metastatic disease: a treatment-free
             interval of at least 6 months prior to enrollment

          -  Participants with any programmed death-ligand 1 (PD-L1) test result by
             immunohistochemistry (IHC) are eligible for the study

          -  Participants without a PD-L1 test result are eligible for the study

          -  Measurable disease per RECIST v1.1

          -  Adequate hematologic and end-organ function

          -  Agreement to remain abstinent (refrain from heterosexual intercourse) or use
             contraceptive methods among women of childbearing potential

        Exclusion Criteria:

          -  Prior treatment with immunotherapy for any stage NSCLC, including early-stage
             (neoadjuvant or adjuvant) disease

          -  Participants with epidermal growth factor receptor (EGFR) sensitizing mutations and
             anaplastic lymphoma kinase (ALK) rearrangements

          -  Active central nervous system (CNS) metastases requiring treatment

          -  Spinal cord compression not definitively treated or not clinically stable

          -  Leptomeningeal disease

          -  Uncontrolled tumor-related pain

          -  Uncontrolled pleural, pericardial effusions, or ascites requiring recurrent drainage
             procedures

          -  Uncontrolled or symptomatic hypercalcemia

          -  Malignancies other than NSCLC within 5 years prior to enrollment, except for those
             curatively treated with negligible risk of metastasis or death

          -  Pregnant or lactating women

          -  History of autoimmune disease, significant pulmonary disease, or significant
             cardiovascular disease

          -  Positive human immunodeficiency virus (HIV) or hepatitis B or C

          -  Active tuberculosis

          -  Severe infection or major surgery within 4 weeks, or oral or IV antibiotics treatment
             within 2 weeks prior to enrollment

          -  Prior treatment with or hypersensitivity to study drug or related compounds

          -  Prior allogeneic bone marrow or solid organ transplant

          -  Administration of a live, attenuated vaccine within 4 weeks prior to enrollment

          -  Treatment with systemic immunostimulatory agents within 4 weeks or 5 half-lives of the
             drug (whichever is longer) prior to enrollment

          -  Treatment with systemic corticosteroids or other systemic immunosuppressive
             medications within 2 weeks prior to enrollment